Skip to main content
ACUT
OTC Life Sciences

AccuStem Q3: $15,303 Cash Left, Going Concern Reaffirmed, $1.5M IPR&D Charge

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.118
Mkt Cap
$1.897M
52W Low
$0.117
52W High
$2.33
52W Position info
0.9% above low
Off High info
95% below high
Rel. Volume
Market data snapshot near publication time

ACUT is trading near its 52-week low of $0.117 (0.9% above the low).

Summary

AccuStem's Q3 10-Q shows only $15,303 of cash, a $5.98M working capital deficit, and a reaffirmed going concern warning, with the $1.87M quarterly loss driven by a $1.5M non-cash IPR&D write-off. The company is surviving on related-party funding and says it is pursuing new equity financing.


Key Events · Earnings and Guidance · ACUT

  • Going Concern Warning Reaffirmed

    Management states the company does not have sufficient cash and current assets to support operations for at least 12 months from the issuance date of these financial statements.

  • Cash Down to $15,303

    Cash was $15,303 at September 30, 2026 against total current liabilities of $6,063,330, leaving a working capital deficit of $5,980,129.

  • $1.5M Non-Cash IPR&D Charge

    The Gensignia IP Limited acquisition closed in the quarter and the acquired in-process R&D was expensed under ASC 730, driving the $1,869,895 Q3 net loss versus $399,897 a year earlier.

  • Survival Rests on Related-Party Funding

    Related party payable to Tiziana reached $5,363,673, including $4,286,500 of funding support and $935,000 of advances during the nine months; Tiziana owns about 10.91% of the company.


Analysis · ACUT · Life Sciences

AccuStem ended September with just $15,303 of cash against $6.06M of current liabilities, and management explicitly says it cannot fund operations for the next 12 months without new money. The quarter's $1.87M loss is mostly a non-cash $1.5M write-off of the Gensignia IPR&D, but the cash position is the real story: the company is being kept alive by Tiziana, which has now advanced $4.29M in funding support and is owed $5.36M in total. Management says it is in discussions for a private investment and public equity raise — any deal done at today's $0.118 price would be deeply dilutive to the 16.07M shares outstanding. The material weakness in financial reporting controls remains unremediated.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ACUT was trading at $0.12 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.9M. The 52-week trading range was $0.12 to $2.33. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ACUT - Latest Insights

ACUT
Aug 14, 2026, 4:06 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.156
Real-time Price: $0.118 info
Change: Low Volume info
Market Cap: $1.897M info
ACUT
May 15, 2026, 4:11 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.2609
Real-time Price: $0.118 info
Change: Low Volume info
Market Cap: $1.897M info
ACUT
May 15, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.2609
Real-time Price: $0.118 info
Change: Low Volume info
Market Cap: $1.897M info
ACUT
Apr 14, 2026, 4:30 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $0.345
Real-time Price: $0.118 info
Change: Low Volume info
Market Cap: $1.897M info